The Technical Analyst
Select Language :
ChemoCentryx, Inc. [CCXI]

Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology

ChemoCentryx, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

ChemoCentryx, Inc. is listed at the NASDAQ Exchange

0.00% $51.99

/ 19 okt 2022 @ 16:00


ChemoCentryx, Inc.: Main Fundamentals PE comparison

RATING 2022-10-20
B+
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Neutral
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
1/212/213/214/211/222/22
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -25.93 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
0x
Company: PE -25.93 | industry: PE 0
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 51.61 - 52.37

( +/- 0.73%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-10-20 Jain Rita Sell 11 600 Restricted Stock Unit
2022-10-20 Herron Jennifer Lyn Sell 17 237 Common Stock
2022-10-20 Edwards Thomas A. Sell 15 723 Restricted Stock Unit
2022-10-20 Parker Geoffrey M. Sell 15 723 Restricted Stock Unit
2022-10-20 Kanaya Susan M Sell 90 968 Restricted Stock Unit
INSIDER POWER
-56.16
Last 97 transactions
Buy: 1 451 999 | Sell: 1 420 462

Forecast: 01:40 - $59.05

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $51.99 (0.00% )
Volume 0.656 mill
Avg. Vol. 2.02 mill
% of Avg. Vol 32.48 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for ChemoCentryx, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for ChemoCentryx, Inc.

RSI

Intraday RSI14 chart for ChemoCentryx, Inc.

Last 10 Buy & Sell Signals For CCXI

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            ChemoCentryx, Inc.

CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.

Last 10 Buy Signals

Date Signal @
DPXUSDMar 29 - 02:4542.45
WBTUSDMar 29 - 02:428.37
TUSDUSDMar 29 - 02:41$0.994
BGBUSDMar 29 - 02:300.996
PEPECOINUSDMar 29 - 02:245.83
VRXUSDMar 29 - 02:1960.44
^N300Mar 29 - 02:00594.52
CBKUSDMar 29 - 02:151.087
ORCAUSDMar 29 - 02:153.83
TRXUSDMar 29 - 02:10$0.120

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.